Fig. 4
From: Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation
Tofacitinib downregulates gene expression of antiviral OAS2. Keratinocytes (n = 5–8) were stimulated for 60 min with tofacitinib before addition of the respective cytokine or bacterial component. OAS2 gene expression is shown for controls (a), tofacitinib in combination with LPS or LTA (b), in combination with IL-17 or IL-22 (c), or tofacitinib combined with IFN-γ or IL-29 (d). The gene expression was analysed via qPCR. Statistical analysis was done using the Mann-Whitney U test. Significances that were compared to untreated control are depicted directly above the stimulatory agent or the compared conditions are indicated by lines and depicted as follows: *P ≤ 0.05 and ***P ≤ 0.001